Riskpilot← Back to searchSign inGet full accessDrSvar Sweden AB
ABActiveOrg 5592533250Österlånggatan 40Other human health activities n.e.c. · NACE 8699Est. 20206 employees
Revenue 2024
SEK 0
EBITDA margin
—
+86% vs 2023
Equity ratio
89.6%
Financial strength
Net profit 2024
SEK -19K
+78% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -6K | +86% |
| Net profit | SEK -19K | +78% |
| Total assets | SEK 3,4M | -23% |
| Equity | SEK 3,1M | -30% |
| Employees | 6 | — |
Legal name
DrSvar Sweden AB
Org number
5592533250
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
23 april 2020
Share capital
SEK 25 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget skall bedriva verksamhet där patienter kan utredas avseende förekomst av STAS-Covid-2-virus via PCR och anti- gentester inkluderande där påföljande utredningsmetoder jämte förenlig verksamhet.
Address
Österlånggatan 40
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 22 612 | 5 685 | 2 | 0 |
| Staff expenses | — | — | −3 371 | −0 | — |
| EBITDA | −2 | 7 862 | −944 | −40 | −6 |
| Depreciation & amort. | −0 | −0 | — | −13 | −13 |
| EBIT | −2 | 7 862 | −944 | −54 | −19 |
| Net financials | — | −11 | −6 | −32 | 0 |
| Profit before tax | −2 | 7 851 | −950 | −86 | −19 |
| Tax | −0 | −1 618 | — | — | — |
| Net profit | −2 | 6 233 | −950 | −86 | −19 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 25 | 9 685 | 7 109 | 4 480 | 3 430 |
| Equity | 22 | 6 255 | 5 306 | 4 382 | 3 073 |
| Long-term debt | 0 | 0 | — | — | 266 |
| Short-term debt | 2 | 3 430 | 1 803 | 99 | 92 |
| Total debt | 2 | 3 430 | 1 803 | 99 | 357 |
EBITDA margin
-566000.0%
This company
15.8%
Market median
-3582378% vs market
20202024
Equity ratio
89.6%
This company
38.2%
Market median
+135% vs market
20202024
Return on equity
-0.6%
This company
18.4%
Market median
-103% vs market
20202024
Net profit margin
-1875100.0%
This company
8.1%
Market median
-23149483% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of DrSvar Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Foad Kuhpai | Deputy Board Member | 0 companies |
| Ferdinand Loniakan | Deputy Board Member | 0 companies |
| Navid Loniakan | Board of Directors | 0 companies |